radiopharmaceuticals

Summary

Summary: Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)

Top Publications

  1. ncbi Recommendations on the use of 18F-FDG PET in oncology
    James W Fletcher
    Department of Radiology, Indiana Purdue University, Indiana University School of Medicine, Indianapolis, Indiana 46202 5253, USA
    J Nucl Med 49:480-508. 2008
  2. pmc From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors
    Richard L Wahl
    Division of Nuclear Medicine, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 0817, USA
    J Nucl Med 50:122S-50S. 2009
  3. ncbi Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
  4. ncbi Consensus nomenclature for in vivo imaging of reversibly binding radioligands
    Robert B Innis
    National Institute of Mental Health, Molecular Imaging Branch, Bethesda, Maryland, USA
    J Cereb Blood Flow Metab 27:1533-9. 2007
  5. pmc FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
    Ronald Boellaard
    Department of Nuclear Medicine and PET Research, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 37:181-200. 2010
  6. pmc Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper
    Mette Munk Jensen
    Cluster for Molecular Imaging, University of Copenhagen, Copenhagen, Denmark
    BMC Med Imaging 8:16. 2008
  7. ncbi Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography
    J H F Rudd
    Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Circulation 105:2708-11. 2002
  8. pmc Lutetium-labelled peptides for therapy of neuroendocrine tumours
    B L R Kam
    Department of Nuclear Medicine, Erasmus MC, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 39:S103-12. 2012
  9. ncbi GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting
    Meike Korner
    Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Bern, Bern, Switzerland
    J Nucl Med 48:736-43. 2007
  10. ncbi Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT
    Damian Wild
    Clinic and Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    J Nucl Med 51:1059-67. 2010

Research Grants

  1. MIBG ANALOGUE RADIOPHARMACEUTICALS
    Ganesan Vaidyanathan; Fiscal Year: 2001
  2. Phage Display for Improved Peptide-based Tumor Targeting and Imaging Agents
    Susan L Deutscher; Fiscal Year: 2013
  3. NOVEL PET AGENT FOR MYOCARDIAL PERFUSION IMAGING
    Vijay Sharma; Fiscal Year: 2013
  4. PSMA-based Cancer Imaging Agents
    Martin G Pomper; Fiscal Year: 2013
  5. ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES
    Michael Rod Zalutsky; Fiscal Year: 2013
  6. DEVELOPMENT OF PET RADIOPHARMACEUTICALS TARGETING GRPR
    Buck E Rogers; Fiscal Year: 2012
  7. State-of-the-Art PET/CT Instrumentation
    Richard E Carson; Fiscal Year: 2010
  8. Correlative Studies for NCI Study#7916: Phase I Clinical Trial of Intravenous FAU
    Patricia Mucci LoRusso; Fiscal Year: 2010
  9. State-of-the-Art Small Animal PET/CT Instrumentation
    Richard E Carson; Fiscal Year: 2013
  10. Cyclotron for PET Radiopharmaceuticals
    Jogeshwar Mukherjee; Fiscal Year: 2013

Detail Information

Publications327 found, 100 shown here

  1. ncbi Recommendations on the use of 18F-FDG PET in oncology
    James W Fletcher
    Department of Radiology, Indiana Purdue University, Indiana University School of Medicine, Indianapolis, Indiana 46202 5253, USA
    J Nucl Med 49:480-508. 2008
    ..Outcomes of interest included the use of (18)F-FDG PET for diagnosing, staging, and detecting the recurrence or progression of cancer...
  2. pmc From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors
    Richard L Wahl
    Division of Nuclear Medicine, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 0817, USA
    J Nucl Med 50:122S-50S. 2009
    ..1. This article also reviews qualitative and quantitative approaches to metabolic tumor response assessment with (18)F-FDG PET and proposes a draft framework for PET Response Criteria in Solid Tumors (PERCIST), version 1.0...
  3. ncbi Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
    ..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...
  4. ncbi Consensus nomenclature for in vivo imaging of reversibly binding radioligands
    Robert B Innis
    National Institute of Mental Health, Molecular Imaging Branch, Bethesda, Maryland, USA
    J Cereb Blood Flow Metab 27:1533-9. 2007
    ..An international group of experts in pharmacokinetic modeling recommends a consensus nomenclature to describe in vivo molecular imaging of reversibly binding radioligands...
  5. pmc FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
    Ronald Boellaard
    Department of Nuclear Medicine and PET Research, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 37:181-200. 2010
    ....
  6. pmc Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper
    Mette Munk Jensen
    Cluster for Molecular Imaging, University of Copenhagen, Copenhagen, Denmark
    BMC Med Imaging 8:16. 2008
    ..Furthermore, we evaluated the accuracy of tumor volume determined from 18F-fluorodeoxyglucose (18F-FDG) PET...
  7. ncbi Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography
    J H F Rudd
    Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Circulation 105:2708-11. 2002
    ..In this study we tested whether 18FDG-PET imaging can identify inflammation within carotid artery atherosclerotic plaques...
  8. pmc Lutetium-labelled peptides for therapy of neuroendocrine tumours
    B L R Kam
    Department of Nuclear Medicine, Erasmus MC, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 39:S103-12. 2012
    ..If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable neuroendocrine tumours...
  9. ncbi GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting
    Meike Korner
    Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Bern, Bern, Switzerland
    J Nucl Med 48:736-43. 2007
    ..Anticipating a major development of GLP-1 receptor targeting in nuclear medicine, our aim was to evaluate in vitro the GLP-1 receptor expression in a large variety of other tumors and to compare it with that in nonneoplastic tissues...
  10. ncbi Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT
    Damian Wild
    Clinic and Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    J Nucl Med 51:1059-67. 2010
    ..The aim of this study was the preclinical evaluation of [Lys(40)(Ahx-DOTA-(68)Ga)NH(2)]-exendin-4 for PET/CT and [Lys(40)(Ahx-hydrazinonicotinamide [HYNIC]-(99m)Tc)NH(2)]-exendin-4 for SPECT/CT...
  11. ncbi Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
    Malik E Juweid
    Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 25:571-8. 2007
    ..To develop guidelines for performing and interpreting positron emission tomography (PET) imaging for treatment assessment in patients with lymphoma both in clinical practice and in clinical trials...
  12. ncbi [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease
    M A Mintun
    Department of Radiology, Washington University School of Medicine, St Louis, MO 63110, USA
    Neurology 67:446-52. 2006
    ..The authors used this imaging technique to investigate whether abnormal binding occurs in clinically normal individuals, prior to the development of cognitive changes...
  13. ncbi Impact of animal handling on the results of 18F-FDG PET studies in mice
    Barbara J Fueger
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Nucl Med 47:999-1006. 2006
    ..The aim of this study was to determine how these factors affect assessment of tumor glucose use by (18)F-FDG PET and to develop an imaging protocol that optimizes visualization of tumor xenografts...
  14. ncbi Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG
    Wei Chen
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    J Nucl Med 46:945-52. 2005
    ..We characterized (18)F-FLT PET of brain gliomas and compared (18)F-FLT with (18)F-FDG PET in side-by-side studies of the same patients...
  15. ncbi PET-MRI fusion in head-and-neck oncology: current status and implications for hybrid PET/MRI
    Denys J Loeffelbein
    Department of Oral and Maxillofacial Surgery, Technische Universitat Munchen, Munchen, Germany
    J Oral Maxillofac Surg 70:473-83. 2012
    ..To review the current status and clinical effect of PET-MRI image fusion in the staging of head-and-neck cancer and to show its implications for imaging with future hybrid PET/MRI scanners...
  16. ncbi Psychosocial stress is associated with in vivo dopamine release in human ventromedial prefrontal cortex: a positron emission tomography study using [¹⁸F]fallypride
    Johan Lataster
    Department of Psychiatry and Neuropsychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University Medical Center, Maastricht, The Netherlands
    Neuroimage 58:1081-9. 2011
    ....
  17. ncbi Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers
    Anna Imhof
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, Basel, Switzerland
    J Clin Oncol 29:2416-23. 2011
    ..To investigate response, survival, and safety profile of the somatostatin-based radiopeptide (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) in neuroendocrine cancers...
  18. ncbi Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose
    Abdelkarim S Allal
    Division of Radiation Oncology, Geneva University Hospital, 24 Rue Micheli du Crest, 1211 Geneva 14, Switzerland
    Int J Radiat Oncol Biol Phys 59:1295-300. 2004
    ..Pretreatment FDG uptake was evaluated as a predictor of local control (LC) and disease-free survival (DFS) in patients with head-and-neck cancer managed primarily either by radiotherapy (RT) or surgery...
  19. ncbi 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors
    Andreas H Jacobs
    Laboratory for Gene Therapy and Molecular Imaging, Max Planck Institute for Neurological Research, Cologne, Germany
    J Nucl Med 46:1948-58. 2005
    ..Additionally, the longer half-life might permit differentiation between transport and intracellular phosphorylation...
  20. ncbi Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocr Relat Cancer 17:R53-73. 2010
    ..side effects of this therapy are few and mild, and the median duration of the therapy response for these radiopharmaceuticals is 30 and 40 months respectively...
  21. pmc Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer
    J Sven D Mieog
    Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
    Ann Surg Oncol 18:2483-91. 2011
    ..Near-infrared (NIR) fluorescent sentinel lymph node (SLN) mapping in breast cancer requires optimized imaging systems and lymphatic tracers...
  22. ncbi Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate
    Roelf Valkema
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 46:83S-91S. 2005
    ....
  23. pmc Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465
    Ravindra A De Silva
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Nucl Med 52:986-93. 2011
    ..Our results show that (64)Cu-AMD3465 is capable of detecting lesions in a CXCR4-dependent fashion, with high target selectivity, and may offer a scaffold for the synthesis of clinically translatable agents...
  24. pmc The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping
    Susan L Troyan
    Breast Care Center, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Ann Surg Oncol 16:2943-52. 2009
    ..The FLARE imaging system overcomes this major obstacle...
  25. ncbi MR-based automatic delineation of volumes of interest in human brain PET images using probability maps
    Claus Svarer
    Neurobiology Research Unit, University Hospital of Copenhagen, Rigshospitalet, N9201, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Neuroimage 24:969-79. 2005
    ..In addition, the method applies well in elderly subjects, even in the presence of pronounced cerebral atrophy...
  26. ncbi Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography
    Didier Lardinois
    Divisions of Thoracic Surgery, University Hospital of Zurich, Zurich, Switzerland
    N Engl J Med 348:2500-7. 2003
    ....
  27. ncbi 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation
    Shu Hang Ng
    Department of Diagnostic Radiology, Chang Gung Memorial Hospital and Chang Gung University, Taiwan
    J Nucl Med 46:1136-43. 2005
    ..In this prospective study, we evaluated the use of 18F-FDG PET, CT/MRI, and their visual correlation for the identification of primary tumors and cervical nodal metastases of SCC of the oral cavity with histologic correlation...
  28. ncbi FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions
    J Aoki
    Department of Diagnostic Radiology, Gunma University School of Medicine, 3 39 22 Showa machi, Maebashi 371 8511, Japan
    Radiology 219:774-7. 2001
    ..To evaluate the standardized uptake value (SUV) of 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) at positron emission tomography (PET) in the differentiation of benign from malignant bone lesions...
  29. ncbi Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU
    Alfons Verbruggen
    Laboratory of Radiopharmacy, Onderwijs en Navorsing 2, Box 821, Herestraat 49, 3000, Leuven, Belgium
    Eur J Nucl Med Mol Imaging 35:2144-51. 2008
    ..relevant current EU requirements concerning the quality of starting materials and final drug products (the radiopharmaceuticals), the non-clinical safety studies and dosimetry considerations whilst designing a human clinical trial ..
  30. ncbi Effect of respiratory gating on quantifying PET images of lung cancer
    Sadek A Nehmeh
    Department of Medical Physics, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 43:876-81. 2002
    ..We have developed a new technique to gate lung 18F-FDG PET images in synchronization with the respiratory motion to reduce smearing due to breathing and improve quantitation of 18F-FDG uptake in lung lesions...
  31. ncbi ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs
    Jamshed B Bomanji
    Institute of Nuclear Medicine, University College Hospital, 235 Euston Road, London NW1 2BU, UK
    Eur J Nucl Med Mol Imaging 39:S113-25. 2012
    ....
  32. ncbi Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen
    Jean François Daisne
    Head and Neck Oncology Program, St Luc University Hospital, Universite Catholique de Louvain, 10 Ave Hippocrate, 1200 Brussels, Belgium
    Radiology 233:93-100. 2004
    ....
  33. ncbi The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors
    Isis Gayed
    Department of Nuclear Medicine, M D Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA
    J Nucl Med 45:17-21. 2004
    ..Therefore, we compared the roles of (18)F-FDG PET and CT in staging and evaluation of early response to imatinib mesylate therapy in recurrent or metastatic GIST...
  34. ncbi Tracer-cocktail injections for combined pre- and intraoperative multimodal imaging of lymph nodes in a spontaneous mouse prostate tumor model
    Anne C van Leeuwen
    Antoni van Leeuwenhoek Hospital, Division of Diagnostic Oncology, 1066 CX Amsterdam, The NetherlandsAntoni van Leeuwenhoek Hospital, Division of Immunology, 1066 CX Amsterdam, The NetherlandsAntoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Division of Surgical Oncology, 1066 CX Amsterdam, The Netherlands
    J Biomed Opt 16:016004. 2011
    ..Furthermore, this approach improves fluorescent-based guidance and enables both accurate surgical planning and intraoperative detection, based on a single injection...
  35. pmc In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer
    Kimberly A Lears
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA
    J Nucl Med 52:470-7. 2011
    ..6.6]-eicosane-1,8-diamine) (SarAr) chelator to bombesin(7-14), radiolabel the conjugate with (64)Cu, and evaluate in vitro and in vivo...
  36. ncbi Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials
    Lalitha K Shankar
    Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Nucl Med 47:1059-66. 2006
  37. ncbi Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study
    Arnold F Jacobson
    GE Healthcare, Princeton, New Jersey, USA
    J Am Coll Cardiol 55:2212-21. 2010
    ....
  38. ncbi Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer
    Ursula Nestle
    Department for Nuclear Medicine, Saarland University Medical Center, Homburg Saar, Germany
    J Nucl Med 46:1342-8. 2005
    ..This investigation compared the gross tumor volumes (GTVs) resulting from 4 methods used for this purpose in a set of clinical cases...
  39. ncbi Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 13:3552-8. 2007
    ....
  40. ncbi FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer
    Si Yeol Song
    Department of Radiation Oncology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea
    Int J Radiat Oncol Biol Phys 63:1053-9. 2005
    ..To assess the efficacy of 18Fluorodeoxyglucose-positron emission tomography (FDG-PET) for predicting a pathologic response in locally advanced esophageal cancer after neoadjuvant chemoradiotherapy...
  41. ncbi Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review
    Hein J Verberne
    Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, F2 238, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    Eur Heart J 29:1147-59. 2008
    ..To derive a more precise estimate of the prognostic significance of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters [early heart mediastinal ratio (H/M), late H/M, and myocardial washout] in heart failure (HF)...
  42. ncbi EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology
    B Hesse
    Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
    Eur J Nucl Med Mol Imaging 32:855-97. 2005
    ..imaging of myocardial perfusion and viability are presented in 13 sections covering patient information, radiopharmaceuticals, injected activities and dosimetry, stress tests, imaging protocols and acquisition, quality control and ..
  43. ncbi Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0
    Dominique Delbeke
    Vanderbilt University Medical Center, Nashville, Tennessee 37232 2675, USA
    J Nucl Med 47:885-95. 2006
  44. ncbi 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules
    Andreas K Buck
    Department of Nuclear Medicine, Universit of Ulm, Germany
    Cancer Res 62:3331-4. 2002
    ..0001; r = 0.87). FLT uptake was specific for malignant lesions and may be used for differential diagnosis of SPNs, assessment of proliferation, and estimation of prognosis...
  45. ncbi The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors
    Andrea Frilling
    Department of General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany
    Ann Surg 252:850-6. 2010
    ..To evaluate the impact of 68Ga-DOTATOC positron emission tomography (PET)/computed tomography (CT) on the multimodal management of neuroendocrine tumors (NET)...
  46. ncbi Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism
    Olga T Hardy
    Division of Endocrinology, The Children s Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA
    J Clin Endocrinol Metab 92:4706-11. 2007
    ..This study evaluated the accuracy of 18F-fluoro-l-dihydroxyphenylalanine ([18F]DOPA) positron emission tomography (PET) scans in diagnosing focal vs. diffuse disease and identifying the location of focal lesions...
  47. pmc Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial
    Maarten L J Smits
    Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, E01, 132, 3584 CX Utrecht, The Netherlands
    J Exp Clin Cancer Res 29:70. 2010
    ..Previous studies have demonstrated the safety of 166Ho-PLLA-MS radioembolization ( 166Ho-RE) in animals. The aim of this phase I trial is to assess the safety and toxicity profile of 166Ho-RE in patients with liver metastases...
  48. ncbi Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis
    M K Gould
    Pulmonary Section 111P, VA Palo Alto Health Care System, 3801 Miranda Ave, Palo Alto, CA 94304, USA
    JAMA 285:914-24. 2001
    ..Focal pulmonary lesions are commonly encountered in clinical practice, and positron emission tomography (PET) with the glucose analog 18-fluorodeoxyglucose (FDG) may be an accurate test for identifying malignant lesions...
  49. ncbi Standards for PET image acquisition and quantitative data analysis
    Ronald Boellaard
    Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
    J Nucl Med 50:11S-20S. 2009
    ..Special attention is given to the rationale underlying certain recommendations and to some of the differences in various guidelines...
  50. pmc Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET)
    Monica Shokeen
    Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Acc Chem Res 42:832-41. 2009
    ..significant achievements, such as the development of more sensitive imaging instruments and robust, safer radiopharmaceuticals, thereby providing more choices to fit personalized medical needs...
  51. ncbi Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques
    Martin Gotthardt
    Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Nucl Med 51:1937-49. 2010
    ....
  52. ncbi Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic Nuclear Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095 6948, USA
    J Nucl Med 48:78S-88S. 2007
    ..From these data, we believe, has emerged reliable evidence in support of the notion that PET/CT offers diagnostic advantages over its individual components for the major cancers...
  53. ncbi Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment
    Patsuree Cheebsumon
    Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
    J Nucl Med 52:1550-8. 2011
    ..The purpose of this study was to assess test-retest variability of tumor delineation methods, with emphasis on the effects of several image characteristics (e.g., resolution and contrast)...
  54. ncbi Skeletal PET with 18F-fluoride: applying new technology to an old tracer
    Frederick D Grant
    Division of Nuclear Medicine PET, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    J Nucl Med 49:68-78. 2008
    ..With the widespread availability of PET scanners and the improved logistics for the delivery of (18)F radiopharmaceuticals, prior limitations to the routine use of (18)F-fluoride bone imaging have largely been overcome...
  55. pmc Cerenkov luminescence imaging of medical isotopes
    Alessandro Ruggiero
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 51:1123-30. 2010
    ..Here, we report the use of the inherent optical emissions from the decay of radiopharmaceuticals for Cerenkov luminescence imaging (CLI) of tumors in vivo and correlate the results with those obtained ..
  56. ncbi Stress protocols and tracers
    Milena J Henzlova
    J Nucl Cardiol 13:e80-90. 2006
  57. ncbi Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
    Lisa Bodei
    Division of Nuclear Medicine, European Institute of Oncology, Via G Ripamonti 435, 20141 Milan, Italy
    Eur J Nucl Med Mol Imaging 35:1847-56. 2008
    ..The kidney is the critical organ and despite renal protection, function loss may become evident years later. The aim of this study was to analyse renal parameters in patients who had undergone dosimetry before PRRT...
  58. ncbi Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine
    Edgar J Rolleman
    Department of Nuclear Medicine, Erasmus Medical Centre, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 30:9-15. 2003
    ..Because Lys75 produced serious hyperkalaemia, it is not suitable for clinical use. LysArg, however, is effective in offering renal protection in PRRT and is safe...
  59. ncbi 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography
    Henryk Barthel
    Cancer Research United Kingdom PET Oncology Group, Department of Cancer Medicine, Faculty of Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London W12 0NN, United Kingdom
    Cancer Res 63:3791-8. 2003
    ..The decrease in [(18)F]FLT uptake after 5-FU was more pronounced than that of [(18)F]FDG. [(18)F]FLT is, therefore, a promising marker for monitoring antiproliferative drug activity in oncology that warrants additional testing...
  60. pmc Prediction of cognitive decline by positron emission tomography of brain amyloid and tau
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA 90024, USA
    Arch Neurol 69:215-22. 2012
    ..To determine whether 2-(1-{6-[(2-fluorine 18-labeled fluoroethyl)methylamino]-2-napthyl}ethylidene) malononitrile ([(18)F]FDDNP) brain regional values in individuals without dementia predict and correlate with future cognitive change...
  61. pmc Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes
    Karen P Chu
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA, USA
    Int J Radiat Oncol Biol Phys 83:1521-7. 2012
    ..We hypothesized that increases in MTV over time would correlate with tumor growth and biology, and would predict outcome. We sought to examine tumor growth over time in serial pretreatment PET-CT scans...
  62. ncbi Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography
    Kunihiko Izuishi
    Department of Gastroenterological Surgery, Kagawa University, 1750 11, Ikenobe, Miki, Kita, Takamatsu, Kagawa, 761 0793, Japan
    J Gastrointest Surg 16:394-400. 2012
    ..In this study, we examined the molecular mechanism underlying the detection of colorectal cancers by FDG-PET...
  63. ncbi (18)FDG-PET/CT for detecting distant metastases and second primary cancers in patients with head and neck cancer. A meta-analysis
    Guo Zeng Xu
    Department of Radiation Oncology, Cancer Hospital of Guangxi Region, Nanning, People s Republic of China
    Oral Oncol 47:560-5. 2011
    ..18)FDG-PET/CT has good diagnostic performance in detecting distant metastases and second primary cancers in patients with HNC...
  64. ncbi FDG PET of infection and inflammation
    Charito Love
    Division of Nuclear Medicine, Long Island Jewish Medical Center, 270 05 76th Ave, New Hyde Park, NY 11040, USA
    Radiographics 25:1357-68. 2005
    ....
  65. ncbi Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid
    Shankar Vallabhajosula
    Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Weill Cornell Medical College of Cornell University and New York Presbyterian Hospital, NY, USA
    Semin Nucl Med 41:283-99. 2011
    ..article provides a brief review of the amyloid biology and chemistry of Aβ-specific (11)C and (18)F-PET radiopharmaceuticals. Clinical trials have clearly documented that PET radiopharmaceuticals capable of assessing Aβ content in ..
  66. ncbi Is the Chronic Kidney Disease Epidemiology Collaboration four-level race equation better than the cystatin C equation?
    Xin Du
    Department of Nephrology, Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing, China
    Nephrology (Carlton) 17:407-14. 2012
    ....
  67. ncbi Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer
    Hyun Hoon Chung
    Department of Obstetrics and Gynecology, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    Ann Surg Oncol 19:1966-72. 2012
    ..The purpose of this study was to investigate the relationship between functional tumor parameters (MTV and TLG) and clinical outcomes in patients with epithelial ovarian cancer (EOC)...
  68. ncbi Radiolabeled amino acids: basic aspects and clinical applications in oncology
    P L Jager
    Department of Nuclear Medicine, PET Center, University Hospital Groningen, Groningen, The Netherlands
    J Nucl Med 42:432-45. 2001
    ..The general feasibility of amino acid imaging in other tumor types has sufficiently been shown, but more research is required in larger patient series and in well-defined clinical settings...
  69. ncbi The diagnosis and management of malignant phaeochromocytoma and paraganglioma
    Alexandra Chrisoulidou
    Department of Endocrinology and Endocrine Oncology, Theagenion Hospital, Thessaloniki, Greece
    Endocr Relat Cancer 14:569-85. 2007
    ..metastatic phaeochromocytoma and paraganglioma and helps identify patients suitable for treatment with radiopharmaceuticals. The 5-year mortality rate of patients with malignant phaeochromocytomas and paragangliomas greater than 50%..
  70. ncbi Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung
    Ryo Takahashi
    Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Clin Cancer Res 18:220-8. 2012
    ..We investigated whether a change in [(18)F]FDG uptake at 2 days of gefitinib treatment predicts outcome in patients with lung adenocarcinoma...
  71. pmc Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids
    Tarun Jindal
    Department of General Surgery, All India Institute of Medical Sciences, New Delhi, India
    Cancer Imaging 11:70-5. 2011
    ..001) in typical carcinoids compared with atypical carcinoids. The different uptake patterns on [18F]FDG and [68Ga]DOTATOC-PET/CT. and the ratio of SUVmax may be helpful in differentiating between typical and atypical carcinoids...
  72. ncbi Intratumoral metabolic heterogeneity of cervical cancer
    Elizabeth A Kidd
    Department of Radiation Oncology, Mallinckrodt Institute of Radiology, Washington University Medical Center, St Louis, Missouri, USA
    Clin Cancer Res 14:5236-41. 2008
    ..The purpose of this study was to evaluate the pretreatment intratumoral metabolic heterogeneity of FDG...
  73. ncbi The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis
    Martin Fuchs
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031 Basel, Switzerland
    Eur J Nucl Med Mol Imaging 39:344-53. 2012
    ..We aimed to assess the impact of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) on the management of patients with suspected large vessel vasculitis...
  74. ncbi Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality
    C C Ling
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 47:551-60. 2000
    ....
  75. ncbi Radiopharmaceutical development of radiolabelled peptides
    Melpomeni Fani
    Department of Nuclear Medicine, University Hospital Freiburg, Hugstetterstrasse 55, 79106 Freiburg, Germany
    Eur J Nucl Med Mol Imaging 39:S11-30. 2012
    ..g. metabolic stability and pharmacokinetics. Herein, we discuss the development of peptides as radiopharmaceuticals starting from the choice of the labelling method and the conditions to the design and optimization of the ..
  76. ncbi Feasibility of simultaneous PET/MR imaging in the head and upper neck area
    Andreas Boss
    Department of Diagnostic and Interventional Radiology, Eberhard Karls University, Tubingen, Germany
    Eur Radiol 21:1439-46. 2011
    ..The aim of this pilot study was to test and demonstrate the feasibility of simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI) of the head and upper neck area using a new hybrid PET/MRI system...
  77. ncbi Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy
    Bieke Lambert
    Division of Nuclear Medicine, Ghent University Hospital, Belgium
    Nucl Med Commun 27:223-9. 2006
    ..Besides the applications in oncology 188Re-based therapies have also been pioneered for benign condition such as prevention of re-stenosis following angioplasty and for radiosynovectomy in cases of refractory arthritis...
  78. pmc Assessment of cellular proliferation in tumors by PET using 18F-ISO-1
    Farrokh Dehdashti
    Division of Nuclear Medicine and Radiological Sciences, Edward Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Nucl Med 54:350-7. 2013
    ....
  79. pmc (99m)Tc-DTPA renal dynamic imaging method may be unsuitable to be used as the reference method in investigating the validity of CDK-EPI equation for determining glomerular filtration rate
    Peng Xie
    Department of Nuclear Medicine, The Third Hospital, Hebei Medical University, Shijiazhuang, PR China
    PLoS ONE 8:e62328. 2013
    ....
  80. ncbi (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response
    V Martinez
    Service de médecine interne et immunologie clinique, Unité Mixte de Recherche en Santé 996, Institut National de la Sante et de la Recherche Medicale, Paris, France
    Int J Tuberc Lung Dis 16:1180-5. 2012
    ..To evaluate the potential of (18)F-fluoro-deoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) for early therapeutic intervention in patients with probable or confirmed tuberculosis (TB)...
  81. ncbi Molecular imaging of proliferation in malignant lymphoma
    Andreas K Buck
    Department of Nuclear Medicine, Institute of Pathology, University Hospital Ulm, Ulm, Germany
    Cancer Res 66:11055-61. 2006
    ....
  82. pmc Preclinical evaluation of two 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging
    Milos Petrik
    Clinical Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria
    Eur J Nucl Med Mol Imaging 39:1175-83. 2012
    ..fumigatus infection in rats. Here we report on the further evaluation of the most promising (68)Ga-siderophore candidates, triacetylfusarinine (TAFC) and ferrioxamine E (FOXE)...
  83. ncbi EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma
    David Taieb
    Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix Marseille University, France
    Eur J Nucl Med Mol Imaging 39:1977-95. 2012
    ..These guidelines are intended to present information specifically adapted to European practice...
  84. pmc Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report
    Kazuhiro Namura
    Department of Urology, Yokohama City University Graduate School of Medicine, 3 9 Fukuura kanazawaku Yokohama, 236 0004 Japan
    BMC Cancer 10:667. 2010
    ....
  85. ncbi Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography
    Klaas P Koopmans
    Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands
    J Clin Oncol 26:1489-95. 2008
    ..To evaluate and compare diagnostic sensitivity of positron emission tomography (PET) scanning in carcinoid and islet cell tumor patients with a serotonin and a catecholamine precursor as tracers...
  86. ncbi The next generation of positron emission tomography radiopharmaceuticals in oncology
    Samuel L Rice
    Radiochemistry Service, Department of Radiology and Program in Molecular Pharmacology and Chemistry, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA
    Semin Nucl Med 41:265-82. 2011
    ..biological targets, and the most recent preclinical or clinical data of some of the next generation of PET radiopharmaceuticals. This review, which is by no means exhaustive, has been separated into sections related to the PET ..
  87. ncbi MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation- and atlas-based methods
    Matthias Hofmann
    Department of Empirical Inference, Max Planck Institute for Intelligent Systems, Tubingen, Germany
    J Nucl Med 52:1392-9. 2011
    ..We assessed 2 algorithms for whole-body MRI-based AC (MRAC): a basic MR image segmentation algorithm and a method based on atlas registration and pattern recognition (AT&PR)...
  88. ncbi Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study
    Shigeto Ueda
    Department of Surgery, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, 359 8513, Japan
    Breast Cancer 18:299-308. 2011
    ....
  89. ncbi In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems
    Jered C Garrison
    Harry S Truman Memorial VA Hospital, Columbia, Missouri 65201 5275, USA
    J Nucl Med 48:1327-37. 2007
    ..The study directly compares 64Cu bombesin analogs using the CB-TE2A and DOTA chelation systems in a prostate cancer xenograft SCID (severely compromised immunodeficient) mouse model...
  90. pmc Transcatheter intraarterial therapies: rationale and overview
    Robert J Lewandowski
    Department of Radiology, Section of Interventional Radiology, Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair St, Suite 800, Chicago, IL 60611, USA
    Radiology 259:641-57. 2011
    ..As part of the interventional oncology review series, in this article we describe the rationale behind each of these transcatheter therapies and provide a review of the existing medical literature...
  91. pmc 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors
    Christoph Oehler
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Nucl Med 52:437-44. 2011
    ..The aim of this study was to evaluate (18)F-fluromisonidazole ((18)F-FMISO) PET for monitoring the tumor response to the antivascular compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA; vadimezan)...
  92. ncbi Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors
    Hanwen Zhang
    Division of Radiological Chemistry, Institute of Nuclear Medicine, Department of Radiology, University Hospital, Basel
    Cancer Res 64:6707-15. 2004
    ....
  93. pmc Multiplexed PET probes for imaging breast cancer early response to VEGF₁₂₁/rGel treatment
    Min Yang
    Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu 214063, China
    Mol Pharm 8:621-8. 2011
    ..This preclinical study should be helpful in accelerating anticancer drug development and promoting the clinical translation of molecular imaging...
  94. pmc Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization
    Mattijs Elschot
    Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
    PLoS ONE 6:e26174. 2011
    ..The aim of this study is to quantitatively evaluate and compare the imaging characteristics of these three isotopes, in order that imaging protocols can be optimized and RE studies with varying isotopes can be compared...
  95. pmc The use of alternative forms of graphical analysis to balance bias and precision in PET images
    Jean Logan
    Medical Department, Brookhaven National Laboratory, Upton, New York 11973, USA
    J Cereb Blood Flow Metab 31:535-46. 2011
    ..The variance of the four estimates can serve as a guide to the reliability of the median estimate. This may provide a general method for the generation of parametric images with little bias and good precision...
  96. ncbi Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)
    Damian Wild
    Division of Radiological Chemistry, University Hospital, Basel, Switzerland
    Cancer Res 71:1009-18. 2011
    ..Furthermore, (213)Bi-DOTA-PESIN has a better safety profile than (213)Bi-AMBA, and represents a possible new approach for use in peptide-receptor radionuclide α-therapy treating recurrent prostate cancer...
  97. ncbi Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer
    Arnold C Paulino
    Department of Radiation Oncology, Division of Nuclear Medicine and Molecular Imaging, Emory Clinic and Emory University, Atlanta, GA, USA
    Int J Radiat Oncol Biol Phys 61:1385-92. 2005
    ....
  98. ncbi Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?
    Stephan Walrand
    Center of Nuclear Medicine, Universite Catholique de Louvain, Brussels, Belgium
    Eur J Nucl Med Mol Imaging 38:S57-68. 2011
    ..The potential imaging capabilities with the radioisotopes (87)Y and (88)Y are also considered. Additional studies required to assess specific unaddressed issues are also identified...
  99. ncbi MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor
    Jesse J Parry
    Department of Radiation Oncology, Washington University School of Medicine, 4511 Forest Park Blvd Suite 411, St Louis, MO 63108, USA
    Breast Cancer Res Treat 101:175-83. 2007
    ..Current radiopharmaceuticals have limited sensitivity for detecting small primary lesions and it has been suggested that novel ..
  100. ncbi In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging
    Luigi Aloj
    Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Naples, Italy
    J Nucl Med 45:485-94. 2004
    Regulatory peptides and their analogs are being extensively investigated as radiopharmaceuticals for cancer imaging and therapy...
  101. ncbi Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients
    Mark J Boogers
    Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
    J Am Coll Cardiol 55:2769-77. 2010
    ....

Research Grants65

  1. MIBG ANALOGUE RADIOPHARMACEUTICALS
    Ganesan Vaidyanathan; Fiscal Year: 2001
    ..Strategies to augment tumor-to-normal tissue ratios will be investigated. The outcome of this study should help improve the endoradiotherapy of neuroendocrine tumors and possibly of medulloblastoma. ..
  2. Phage Display for Improved Peptide-based Tumor Targeting and Imaging Agents
    Susan L Deutscher; Fiscal Year: 2013
    ..The radiolabeled conjugates may serve as diagnostic radiopharmaceuticals for the detection of primary and metastatic cancer and indicators of response to therapy...
  3. NOVEL PET AGENT FOR MYOCARDIAL PERFUSION IMAGING
    Vijay Sharma; Fiscal Year: 2013
    ..2) Perform mechanism-based assessment and validation of novel 68Ga-radiopharmaceuticals derived from our focused SAR studies in cardiomyocytes, HEPG2 cells, Pgp- expressing KB cells, Pgp-..
  4. PSMA-based Cancer Imaging Agents
    Martin G Pomper; Fiscal Year: 2013
    ..Although we intend to focus on new, low molecular weight radiopharmaceuticals for PET (Aim 1), we will also develop the good manufacturing practice (GMP) synthesis of the one agent on ..
  5. ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES
    Michael Rod Zalutsky; Fiscal Year: 2013
    ..its [211At]astatobenzoyl Mal-D-GEEEK analogue and to evaluate their potential as diagnostic and therapeutic radiopharmaceuticals;2) investigate strategies for improving the Mal- GEEEK reagent for labeling internalizing mAbs including ..
  6. DEVELOPMENT OF PET RADIOPHARMACEUTICALS TARGETING GRPR
    Buck E Rogers; Fiscal Year: 2012
    ..to evaluate the radiolabeled BN analogs in vivo in mice bearing tumor xenografts as radiopharmaceuticals for PET imaging of GRPR...
  7. State-of-the-Art PET/CT Instrumentation
    Richard E Carson; Fiscal Year: 2010
    ..The need for combined PET/CT will be of even greater importance in research studies using novel radiopharmaceuticals. The interpretation of the spatial localization of a new tracer, where normal uptake patterns are unknown, ..
  8. Correlative Studies for NCI Study#7916: Phase I Clinical Trial of Intravenous FAU
    Patricia Mucci LoRusso; Fiscal Year: 2010
    ..Chemotherapeutic compounds, labeled with positron emitting radiopharmaceuticals, allow biodistribution of the chemotherapeutic to be imaged in vivo, as well as determination of its uptake ..
  9. State-of-the-Art Small Animal PET/CT Instrumentation
    Richard E Carson; Fiscal Year: 2013
    ..The need for combined PET/CT is of even greater importance in research studies using novel radiopharmaceuticals, where the interpretation of the spatial localization of a new tracer cannot be performed without high-..
  10. Cyclotron for PET Radiopharmaceuticals
    Jogeshwar Mukherjee; Fiscal Year: 2013
    ....
  11. 9 Intl Symposium - Functional Neuroreceptor Mapping of the Living Brain NRM 2012
    DEAN FOSTER WONG; Fiscal Year: 2011
    ..e., PET and SPECT imaging of radiopharmaceuticals that image brain neuroreceptor and neurotransmitter systems)...
  12. RECEPTOR-TARGETED COPPER RADIOPHARMACEUTICALS FOR CANCER IMAGING AND THERAPY
    Carolyn J Anderson; Fiscal Year: 2012
    ..have yielded significant discoveries that have contributed to the development of PET and therapeutic radiopharmaceuticals, principally, the labeling of somatostatin analogs with 64Cu (T1/2 = 12.7 h;+ (17.8%);- (38.4%))...
  13. Synthesis and Screening of Peptide and Protein Based Rhenium Carbonyl Compounds a
    Christopher J Ziegler; Fiscal Year: 2012
    ..First, this research will directly contribute to the development of new technetium radiopharmaceuticals that target specific tissues...
  14. Radiopharmaceuticals for Imaging Nuclear Receptors in Breast and Prostate Cancers
    John A Katzenellenbogen; Fiscal Year: 2013
    ..Their biodistribution will then be evaluated in preclinical models of ERR?-positive breast cancers to develop ERR? as a predictive marker for novel therapies for both ER-positive and negative breast cancers. ..
  15. A Novel F-18 PET Myocardial Perfusion Radiopharmaceutical based on Rhodamine Dyes
    ALAN BRENT PACKARD; Fiscal Year: 2013
    ..At the present time, MPI studies are usually carried out using the single-photon radiopharmaceuticals 99mTc-MIBI and 99mTc- tetrofosmin...
  16. Anionic Phospholipid-Selective PET/SPECT Agent for Infection Imaging
    BRIAN DAVID GRAY; Fiscal Year: 2012
    ..is crucial to the management of patients suspected of bacterial infection, the currently available radiopharmaceuticals are not capable of distinguishing between sterile inflammation and bacterial infections...
  17. Novel Combination Therapy Against Pancreatic Cancer
    Maneesh Jain; Fiscal Year: 2012
    ..of tumor vascular flow and tumor stroma would improve the delivery and therapeutic efficacy of targeted radiopharmaceuticals for the treatment of pancreatic cancer...
  18. Imaging Airway Liquid Absorption in Cystic Fibrosis
    TIMOTHY EDWARD CORCORAN; Fiscal Year: 2013
    ..Our imaging technique involves the inhalation of two radiopharmaceuticals: one an absorbable small-molecule (In-DTPA) and the other a non-absorbable particle (Tc-SC)...
  19. Carbon-11 Radiopharmaceutical Production System
    Anna Liisa Brownell; Fiscal Year: 2010
    ..has the highest performance of the commercial systems currently available for production C-11 labeled radiopharmaceuticals. The synthesizer must balance a number of factors in the design to fulfill requirements for performance, ..
  20. PET/CT Imaging System
    William J Jagust; Fiscal Year: 2010
    ..A medical cyclotron at LBNL operated by a radiochemistry research group, produces a wide variety of radiopharmaceuticals for human and animal use...
  21. Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin
    MICHAEL JOHN EVANS; Fiscal Year: 2013
    ..Radiochemist with substantial experience in the preclinical validation and clinical translation of novel radiopharmaceuticals for imaging and therapy. Drs...
  22. PET/CT Imaging of Malignant Brain Tumors with 124I-NM404
    Jamey P Weichert; Fiscal Year: 2013
    ..Even with the use of advanced MRI pulse sequences and PET radiopharmaceuticals, the true extent of tumor infiltration into surrounding normal brain is often inadequately characterized ..
  23. Expanding F-18 Production for PET/CT
    BRUCE WENDELL WIELAND; Fiscal Year: 2010
    ..However, the demand for 18F radiopharmaceuticals other than FDG has recently been predicted to increase dramatically in the next 2-4 years, expanding the ..
  24. A Novel Dose Calculation Method for Targeted Radionuclide Therapy
    Firas Mourtada; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Targeted radiotherapy with internally administered radiopharmaceuticals has recently experienced renewed interest due to identification of better tumor biomarkers and development of new targeting ..
  25. Siemens Eclipse HP Cyclotron for PET Imaging Research
    Chester A Mathis; Fiscal Year: 2010
    ..Realizing these efficiencies is of paramount importance as the RDS-112 presently supplies radiopharmaceuticals for two human Siemens HR+ PET scanners and two preclinical microPET scanners...
  26. Design and Evaluation of Hypoxia Enhanced Bombesin Analogs for Prostate Cancer
    Jered C Garrison; Fiscal Year: 2012
    ..Research Project: Our proposal is to enhance the efficacy of diagnostic radiopharmaceuticals for the detection of prostate cancer by incorporating hypoxia trapping agents into the structure of tumor ..
  27. BIOMEDICAL (BASIC)
    RICHARD TESTA; Fiscal Year: 2009
    ..novel bacteriophage display selected ErbB-2 receptor-targeting peptides into 203Pb/212Pb matched pair radiopharmaceuticals for the imaging and therapy of human breast, lung, and ovarian carcinomas...
  28. A new radiopharmaceutical for the treatment of metastatic bone cancer
    JAIME NMN SIMON; Fiscal Year: 2013
    ..S. each year. "Bone-seeking" radiopharmaceuticals are used for bone pain palliation and have shown promise for treating bone metastases...
  29. PET/CT for quantitative biomarker assessment of disease &early therapy response
    James M Mountz; Fiscal Year: 2013
    ..clinical trials and research studies using sophisticated scanning protocols and/or novel or short lived PET radiopharmaceuticals. This will allow quantitative imaging biomarker characterization of disease states in a wide range of ..
  30. A new radiopharmaceutical for the treatment of metastatic bone cancer
    JAIME NMN SIMON; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): "Bone-seeking" radiopharmaceuticals are used extensively for bone pain palliation and have shown promise for treating bone metastases...
  31. Development of Novel Fluorinated Amino Acids
    Mark Goodman; Fiscal Year: 2004
    ..Our choice of cyclobutyl and branched nonmetabolized amino acids as suitable radiopharmaceuticals for imaging tumors stems from our preliminary in vitro studies in rat 9L gliosarcoma cells demonstrating ..
  32. Small-Animal Optical Imaging System
    Simon R Cherry; Fiscal Year: 2012
    ..carrying luciferase or fluorescent reporter genes, and animals injected with fluorescent imaging agents or radiopharmaceuticals, the latter being studied by the emission of Cerenkov light...
  33. Dedicated Brain PET Device Optimized for Brain Imaging
    DAVID M BEYLIN; Fiscal Year: 2013
    ..Amyloid imaging agents, the new promising class of Positron Emission Tomography (PET) radiopharmaceuticals, enable diagnosis of Alzheimer's pathology at the early stages of disease...
  34. Development of Tc-99m Renal Tubular Tracers
    ANDREW THOMPSON TAYLOR; Fiscal Year: 2013
    ..99mTc and 18F diagnostic radiopharmaceuticals as well as beta-emitting 186Re and 188Re e therapeutic radiopharmaceuticals...
  35. Comb External Beam Radiotherapy with 153Sm-EDTMP to Treat High Risk Osteosarcoma
    David M Loeb; Fiscal Year: 2013
    ..We will use a novel technique, [18F]-MISO PET to test the hypothesis that hypoxia makes tumors resistant to radiopharmaceuticals, just as it contributes to resistance to external beam radiotherapy...
  36. PET Imaging of Cancer with pH (Low) Insertion Peptide (pHLIP)
    Jason S Lewis; Fiscal Year: 2013
    ..of this project is to develop a new approach for the imaging of solid tumors based on pHLIP- based radiopharmaceuticals, with the final goal of translating an agent to the clinic...
  37. Modeling Targeted Alpha Particle Therapy of Cancer
    ROBERT FRANCOIS HOBBS; Fiscal Year: 2013
    ..increased availability of a-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with a-particle emitters with very promising results...
  38. Harmonized PET Reconstructions for Cancer Clinical Trials
    John Sunderland; Fiscal Year: 2013
    ..When combined with radiopharmaceuticals that provide valuable information on the state of malignancies, PET is a potentially powerful imaging ..
  39. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2006
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  40. Chemistry of Reactive Intermediates Generated from Benzothiazole Derived Drug Can
    Michael Novak; Fiscal Year: 2009
    ..have been under rapid development as anti-tumor, antimicrobial, and antifungal agents and as radiopharmaceuticals for binding and in vivo imaging of A?-plaques, one of the earliest pathological processes in the ..
  41. ACS-TR19 CYCLOTRON
    Robert C McKinstry; Fiscal Year: 2012
    ..of features within the TR19 is optimal for supporting the diverse number of PET radionuclides and radiopharmaceuticals needed to support our NIH-funded research...
  42. A Walk-UP LC-MS for the Rapid Analysis of Organic Compounds
    Paul Hergenrother; Fiscal Year: 2010
    ..and antitumor agents, various natural and non-natural products, molecular probes for steroid receptors, radiopharmaceuticals for breast tumor imaging, and small molecule protein mimics for biomedical sensor arrays...
  43. DEVELOPMENT OF CANCER IMAGING AGENTS
    Henry VanBrocklin; Fiscal Year: 2000
    ..The applicants have outlined a paradigm to develop unique positron and single photon emitting radiopharmaceuticals using the epidermal growth factor receptor tyrosine kinase (EGFRtk) and breast cancer as model systems...
  44. Quantitative Cardiac PET
    Georges El Fakhri; Fiscal Year: 2013
    ..Dynamic PET has long been a mainstay for research applications. However, several new PET radiopharmaceuticals require quantitative dynamic imaging with kinetic analysis to reach their clinical potential...
  45. Production System for 18-Labeled Oxygen
    MICHAEL C KIMBLE; Fiscal Year: 2013
    ..This oxygen-18 is converted into fluorinated-18 isotopes to produce radiopharmaceuticals for medical imaging using Positron Emission Tomography (PET)...
  46. Molecular imaging of vascular pathology
    John W Chen; Fiscal Year: 2010
    ..The principal investigator will be co-mentored by Professor Alan Fischman, a recognized expert in radiopharmaceuticals and nuclear/PET radiology, and by Professor Michael Moskowitz, a world-renowned expert in stroke...
  47. Safety and Preliminary Efficacy Imaging Clinical Trials
    Cheryl Robinson; Fiscal Year: 2009
    ..are used to evaluate the safety and diagnostic imaging capabilities of promising imaging probes, ligands, radiopharmaceuticals, and contrast agents that are of interest to NCI...
  48. Safety and Preliminary Efficacy Imaging Clinical Trials
    Richard Wahl; Fiscal Year: 2009
    ..are used to evaluate the safety and diagnostic imaging capabilities of promising imaging probes, ligands, radiopharmaceuticals, and contrast agents that are of interest to NCI...
  49. POTENTIAL TUMOR OR ORGAN IMAGING AGENTS
    RAYMOND COUNSELL; Fiscal Year: 1993
    ..its inception in 1965, the long term goals of this project have been to design, synthesize and evaluate new radiopharmaceuticals as potentials organ or tumor-imaging agents...
  50. Global Shared Memory (GSM) Supercomputer for Quantitative PET Imaging
    Georges El Fakhri; Fiscal Year: 2012
    ..significant advances in nuclear medicine imaging, such as dynamic imaging for kinetic modeling of novel PET radiopharmaceuticals, PET-MR, time-of-flight PET, and quantitative SPECT-CT, that have triggered active research in modeling, ..
  51. PET/CT for Multidimensional Translational Cardiovascular Research
    JOHN CANTY; Fiscal Year: 2009
    ..studies of vascular and myocardial structure coupled with molecular imaging using novel cyclotron generated radiopharmaceuticals developed at the adjacent UB Center for Positron Emission Tomography...
  52. Novel Cationic 99mTc Complexes for Heart Imaging
    Shuang Liu; Fiscal Year: 2006
    ..Thus, there is a continuing need for better 99mTc radiopharmaceuticals for myocardial perfusion imaging...
  53. Beta Imager 2000Z Digital Imaging System
    Jason Lewis; Fiscal Year: 2005
    ..Washington University School of Medicine (WUSM) is a world leader in the concept and design of new radiopharmaceuticals and drugs. Aiding in the screening of new radiopharmaceutieals are two state-of-the-art microPET tomographs...
  54. Development of GRP Receptor-Avid Radiopharmaceuticals
    Timothy Hoffman; Fiscal Year: 2006
    ..the potential for development of one or more radiolabeled Gastrin Releasing Peptide (GRP) receptor-avid radiopharmaceuticals. We propose that these radiopharmaceuticals will be effective site-directed agents, for the treatment and/..
  55. 18F-AV-133, A Novel Radiopharmaceutical for Differential Diagnosis of Dementia
    Franz Hefti; Fiscal Year: 2009
    ..We and others have been developing radiopharmaceuticals that allow detection of A amyloid deposits typical for AD...
  56. A Beta-Sensitive Probe System for Use in Endoscopy
    RAYMOND RAYLMAN; Fiscal Year: 2002
    ..of surgical treatment of cancer utilizing handheld beta-sensitive probes in conjunction with tumor-avid radiopharmaceuticals (such as FDG) have previously been developed...
  57. Intrathecal Cancer Therapy using I131 NaI
    Franklin Wong; Fiscal Year: 2002
    ..On the other hand, the locoregional use of radiopharmaceuticals such as beta-emitters with millimeter ranges may overcome such hurdles...
  58. DEVELOPMENT OF NEW RENAL FUNCTION IMAGING AGENTS
    John Babich; Fiscal Year: 1999
    None of the existing radiopharmaceuticals for measuring renal function in humans accurately measures effective renal plasma flow. The two commercially used agents exhibit extraction efficiencies of only .80 and ...
  59. Antisense imaging of brain gene expression in vivo
    William Pardridge; Fiscal Year: 2003
    ..The only way that specific genes can be imaged is with antisense radiopharmaceuticals. However, these molecules do not cross cell membranes well and do not cross the blood-brain barrier (BBB)...
  60. Higher Oxidation State Astatine-211 Radiopharmaceuticals
    Alexander Yordanov; Fiscal Year: 2003
    ..and evaluation of higher oxidation states At-211 labeling as a novel approach in the preparation of At-211 radiopharmaceuticals. To this end there are four specific aims: i) to develop the optimal chemistry for isolation and ..
  61. THERMOSYPHON TARGETRY TO IMPROVE F-18 PET
    BRUCE WIELAND; Fiscal Year: 2006
    ..unreadable] The overall objective of the proposed work is to reduce the cost of accelerator produced F-18 radiopharmaceuticals used in Positron Emission Tomography (PET), a Medicare-reimbursed nuclear medicine metabolic imaging ..
  62. RADIOPHARMACEUTICALS TARGETED TO TUMOR FOLATE RECEPTORS
    Mark Green; Fiscal Year: 2003
    ..b>Radiopharmaceuticals that exhibit significant tumor uptake and tumor selectivity will be examined in more detail to: (ii) ..
  63. Targeting Tumor Microenvironment with Radiolabeled Inhibitors of Seprase (FAPalph
    JOHN JOYAL; Fiscal Year: 2009
    ..In addition, as radiopharmaceuticals can be prepared that are not only capable of imaging disease but also delivering a therapeutic radionuclide ..
  64. TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
    Alun Jones; Fiscal Year: 2002
    ..study of the basic chemistry of the element and incorporating this knowledge into the design of new radiopharmaceuticals. This is equally true of therapeutic applications based on the use of radionuclides of its congener rhenium...
  65. TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
    Alun Jones; Fiscal Year: 2004
    ..study of the basic chemistry of the element and incorporating this knowledge into the design of new radiopharmaceuticals. This is equally true of therapeutic applications based on the use of radionuclides of its congener rhenium...